FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3183653006> ?p ?o ?g. }

• W3183653006 endingPage "e040823" @default.
• W3183653006 startingPage "e040823" @default.
• W3183653006 abstract "Introduction The improvements in short-term outcome after severe trauma achieved through early resuscitation and acute care can be offset over the following weeks by an acute systemic inflammatory response with immuneparesis leading to infection, multiorgan dysfunction/multiorgan failure (MOF) and death. Serum levels of the androgen precursor dehydroepiandrosterone (DHEA) and its sulfate ester DHEAS, steroids with immune-enhancing activity, are low after traumatic injury at a time when patients are catabolic and immunosuppressed. Addressing this deficit and restoring the DHEA(S) ratio to cortisol may provide a range of physiological benefits, including immune modulatory effects. Objective Our primary objective is to establish a dose suitable for DHEA supplementation in patients after acute trauma to raise circulating DHEA levels to at least 15 nmol/L. Secondary objectives are to assess if DHEA supplementation has any effect on neutrophil function, metabolic and cytokine profiles and which route of administration (oral vs sublingual) is more effective in restoring circulating levels of DHEA, DHEAS and downstream androgens. Methods and analysis A prospective, phase II, single-centre, cross-sectional, randomised study investigating Dehydroepiandrosterone supplementation and its profile in trauma, with a planned recruitment between April 2019 and July 2021, that will investigate DHEA supplementation and its effect on serum DHEA, DHEAS and downstream androgens in trauma. A maximum of 270 patients will receive sublingual or oral DHEA at 50, 100 or 200 mg daily over 3 days. Females aged ≥50 years with neck of femur fracture and male and female major trauma patients, aged 16–50 years with an injury severity score ≥16, will be recruited. Ethics and dissemination This protocol was approved by the West Midlands – Coventry and Warwickshire Research Ethics Committee (Reference 18/WM/0102) on 8 June 2018. Results will be disseminated via peer-reviewed publications and presented at national and international conferences. Trial registration This trial is registered with the European Medicines Agency (EudraCT: 2016-004250-15) and ISRCTN (12961998). It has also been adopted on the National Institute of Health Research portfolio (CPMS ID:38158). Trial progression The study recruited its first patient on 2 April 2019 and held its first data monitoring committee on 8 November 2019. DHEA dosing has increased to 100 mg in both male cohorts and remains on 50 mg in across all female groups." @default.
• W3183653006 created "2021-08-02" @default.
• W3183653006 creator A5002798237 @default.
• W3183653006 creator A5005802538 @default.
• W3183653006 creator A5010324154 @default.
• W3183653006 creator A5019472985 @default.
• W3183653006 creator A5024961246 @default.
• W3183653006 creator A5027299449 @default.
• W3183653006 creator A5027813669 @default.
• W3183653006 creator A5034368418 @default.
• W3183653006 creator A5045998144 @default.
• W3183653006 creator A5047079864 @default.
• W3183653006 creator A5047781083 @default.
• W3183653006 creator A5048287553 @default.
• W3183653006 creator A5060600769 @default.
• W3183653006 creator A5061034331 @default.
• W3183653006 creator A5061074316 @default.
• W3183653006 creator A5066381179 @default.
• W3183653006 creator A5071357903 @default.
• W3183653006 creator A5074983274 @default.
• W3183653006 creator A5076777946 @default.
• W3183653006 creator A5083060682 @default.
• W3183653006 creator A5085164884 @default.
• W3183653006 creator A5070461208 @default.
• W3183653006 date "2021-07-01" @default.
• W3183653006 modified "2023-09-23" @default.
• W3183653006 title "A prospective, phase II, single-centre, cross-sectional, randomised study investigating Dehydroepiandrosterone supplementation and its Profile in Trauma: ADaPT" @default.
• W3183653006 cites W1930926117 @default.
• W3183653006 cites W1944050649 @default.
• W3183653006 cites W1963520818 @default.
• W3183653006 cites W1965370016 @default.
• W3183653006 cites W1976443526 @default.
• W3183653006 cites W1977261421 @default.
• W3183653006 cites W1990754639 @default.
• W3183653006 cites W1995511987 @default.
• W3183653006 cites W1999981983 @default.
• W3183653006 cites W1999997178 @default.
• W3183653006 cites W2005598262 @default.
• W3183653006 cites W2009841772 @default.
• W3183653006 cites W2013980575 @default.
• W3183653006 cites W2014890825 @default.
• W3183653006 cites W2021437097 @default.
• W3183653006 cites W2028573458 @default.
• W3183653006 cites W2032150461 @default.
• W3183653006 cites W2033200013 @default.
• W3183653006 cites W2035826730 @default.
• W3183653006 cites W2037418955 @default.
• W3183653006 cites W2039911931 @default.
• W3183653006 cites W2042821497 @default.
• W3183653006 cites W2044391772 @default.
• W3183653006 cites W2044665795 @default.
• W3183653006 cites W2052889679 @default.
• W3183653006 cites W2054018118 @default.
• W3183653006 cites W2058350561 @default.
• W3183653006 cites W2058850167 @default.
• W3183653006 cites W2059293991 @default.
• W3183653006 cites W2064496002 @default.
• W3183653006 cites W2076122670 @default.
• W3183653006 cites W2076989896 @default.
• W3183653006 cites W2081348604 @default.
• W3183653006 cites W2082792497 @default.
• W3183653006 cites W2084259510 @default.
• W3183653006 cites W2096556922 @default.
• W3183653006 cites W2098752121 @default.
• W3183653006 cites W2101492604 @default.
• W3183653006 cites W2104662014 @default.
• W3183653006 cites W2111168097 @default.
• W3183653006 cites W2114438201 @default.
• W3183653006 cites W2115601885 @default.
• W3183653006 cites W2119323420 @default.
• W3183653006 cites W2120623604 @default.
• W3183653006 cites W2121348616 @default.
• W3183653006 cites W2122433136 @default.
• W3183653006 cites W2124246726 @default.
• W3183653006 cites W2130213534 @default.
• W3183653006 cites W2134388933 @default.
• W3183653006 cites W2138560194 @default.
• W3183653006 cites W2140783655 @default.
• W3183653006 cites W2145347643 @default.
• W3183653006 cites W2150320055 @default.
• W3183653006 cites W2151313460 @default.
• W3183653006 cites W2159733957 @default.
• W3183653006 cites W2161364942 @default.
• W3183653006 cites W2164007663 @default.
• W3183653006 cites W2166023752 @default.
• W3183653006 cites W2168472005 @default.
• W3183653006 cites W2169585002 @default.
• W3183653006 cites W2233513380 @default.
• W3183653006 cites W2593515375 @default.
• W3183653006 cites W2594452637 @default.
• W3183653006 cites W2737162863 @default.
• W3183653006 cites W2914690162 @default.
• W3183653006 cites W2914985005 @default.
• W3183653006 cites W2932731433 @default.
• W3183653006 cites W2955232611 @default.
• W3183653006 cites W2965072442 @default.
• W3183653006 cites W3007632646 @default.
• W3183653006 cites W3136304305 @default.

• next